Product Description
Canakinumab (ACZ885, Ilaris) is a human anti-IL-1beta monoclonal antibody developed by Novartis. its mode of action is based on the neutralization of 1beta signaling, resulting in suppression of inflammation in patients with disorders of autoimmune origin. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828573/)
Mechanisms of Action: IL1 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Korea, Lebanon, Malaysia, Netherlands, Norway, Philippines, Poland, Portugal, Romania, Russia, Singapore, Slovakia, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States, Unknown Location, Vietnam
Active Clinical Trial Count: 33
Highest Development Phases
Phase 3: Adenocarcinoma|Arthritis|Arthritis, Juvenile|COVID-19|Cold Urticaria|Coronavirus Infections|Cryopyrin-Associated Periodic Syndromes|Familial Mediterranean Fever|Lung Cancer|Mevalonate Kinase Deficiency|Non-Small-Cell Lung Cancer|Pancreatic Cancer|Pyoderma Gangrenosum|Small Cell Lung Cancer|Still's Disease, Adult-Onset|Type 2 Diabetes
Phase 2: Acute Monocytic Leukemia|Acute Myelomonocytic Leukemia|Alzheimer Disease|Chronic Myelomonocytic Leukemia|Hepatitis A|Hepatitis, Alcoholic|Juvenile Myelomonocytic Leukemia,|Myelodysplastic Syndrome|Osteoarthritis|Preleukemia
Phase 1: Colorectal Cancer|Healthy Volunteers|Pancreatic Ductal Carcinoma|Renal Cell Carcinoma|Triple Negative Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CANAL | P3 |
Active, not recruiting |
Lung Cancer |
2034-03-14 |
|
| PanCAN_Precision Promise | P3 |
Active, not recruiting |
Pancreatic Cancer|Adenocarcinoma |
2027-06-24 |
|
| CACZ885U2301 | P3 |
Recruiting |
Non-Small-Cell Lung Cancer |
2027-06-07 |
|
| NCI-2019-08494 | P2 |
Recruiting |
Juvenile Myelomonocytic Leukemia,|Preleukemia|Acute Myelomonocytic Leukemia|Myelodysplastic Syndrome|Acute Monocytic Leukemia|Chronic Myelomonocytic Leukemia |
2026-12-31 |